Strategies to improve the efficacy of platinum compounds

Giacomo Cossa, Laura Gatti, Franco Zunino, Paola Perego

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Platinum drugs are widely used in antitumour therapy and are a cornerstone of the treatment of different solid tumours. The pharmacological interest of cisplatin has led to the design of many analogues to broaden the spectrum of activity, reduce side effects, and overcome resistance. Although the cis configuration was initially identified as the only active one, trans-platinum complexes have shown significant antitumour activity in preclinical models. In addition to mononuclear platinum compounds, multinuclear platinum complexes have been generated that are characterised by a different mode of interaction with DNA. Since a major limitation to the clinical efficacy of platinum compounds is drug resistance, the most important feature of nonconventional platinum drugs should be the capability of overcoming cellular resistance. However, due to the multifactorial nature of clinical resistance, which also involves pharmacological factors, the optimisation of current platinum-based therapy also includes the development of drug delivery approaches. The present review focuses on recent studies on the molecular alterations of tumour cells that are associated with resistance to platinum drugs, the development of novel platinum drugs, and approaches that may contribute to improve the efficacy of platinum-based therapy.

Original languageEnglish
Pages (from-to)2355-2365
Number of pages11
JournalCurrent Medicinal Chemistry
Volume16
Issue number19
DOIs
Publication statusPublished - 2009

Fingerprint

Platinum Compounds
Platinum
Pharmaceutical Preparations
Tumors
Pharmacology
Drug delivery
Drug Resistance
Cisplatin
Neoplasms
Therapeutics
Cells
DNA

Keywords

  • Cisplatin
  • Drug delivery
  • Drug resistance
  • Oxaliplatin
  • Polynuclear platinum compounds

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Strategies to improve the efficacy of platinum compounds. / Cossa, Giacomo; Gatti, Laura; Zunino, Franco; Perego, Paola.

In: Current Medicinal Chemistry, Vol. 16, No. 19, 2009, p. 2355-2365.

Research output: Contribution to journalArticle

Cossa, Giacomo ; Gatti, Laura ; Zunino, Franco ; Perego, Paola. / Strategies to improve the efficacy of platinum compounds. In: Current Medicinal Chemistry. 2009 ; Vol. 16, No. 19. pp. 2355-2365.
@article{06fa42117f734bf393c2e09541f1309b,
title = "Strategies to improve the efficacy of platinum compounds",
abstract = "Platinum drugs are widely used in antitumour therapy and are a cornerstone of the treatment of different solid tumours. The pharmacological interest of cisplatin has led to the design of many analogues to broaden the spectrum of activity, reduce side effects, and overcome resistance. Although the cis configuration was initially identified as the only active one, trans-platinum complexes have shown significant antitumour activity in preclinical models. In addition to mononuclear platinum compounds, multinuclear platinum complexes have been generated that are characterised by a different mode of interaction with DNA. Since a major limitation to the clinical efficacy of platinum compounds is drug resistance, the most important feature of nonconventional platinum drugs should be the capability of overcoming cellular resistance. However, due to the multifactorial nature of clinical resistance, which also involves pharmacological factors, the optimisation of current platinum-based therapy also includes the development of drug delivery approaches. The present review focuses on recent studies on the molecular alterations of tumour cells that are associated with resistance to platinum drugs, the development of novel platinum drugs, and approaches that may contribute to improve the efficacy of platinum-based therapy.",
keywords = "Cisplatin, Drug delivery, Drug resistance, Oxaliplatin, Polynuclear platinum compounds",
author = "Giacomo Cossa and Laura Gatti and Franco Zunino and Paola Perego",
year = "2009",
doi = "10.2174/092986709788682083",
language = "English",
volume = "16",
pages = "2355--2365",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - Strategies to improve the efficacy of platinum compounds

AU - Cossa, Giacomo

AU - Gatti, Laura

AU - Zunino, Franco

AU - Perego, Paola

PY - 2009

Y1 - 2009

N2 - Platinum drugs are widely used in antitumour therapy and are a cornerstone of the treatment of different solid tumours. The pharmacological interest of cisplatin has led to the design of many analogues to broaden the spectrum of activity, reduce side effects, and overcome resistance. Although the cis configuration was initially identified as the only active one, trans-platinum complexes have shown significant antitumour activity in preclinical models. In addition to mononuclear platinum compounds, multinuclear platinum complexes have been generated that are characterised by a different mode of interaction with DNA. Since a major limitation to the clinical efficacy of platinum compounds is drug resistance, the most important feature of nonconventional platinum drugs should be the capability of overcoming cellular resistance. However, due to the multifactorial nature of clinical resistance, which also involves pharmacological factors, the optimisation of current platinum-based therapy also includes the development of drug delivery approaches. The present review focuses on recent studies on the molecular alterations of tumour cells that are associated with resistance to platinum drugs, the development of novel platinum drugs, and approaches that may contribute to improve the efficacy of platinum-based therapy.

AB - Platinum drugs are widely used in antitumour therapy and are a cornerstone of the treatment of different solid tumours. The pharmacological interest of cisplatin has led to the design of many analogues to broaden the spectrum of activity, reduce side effects, and overcome resistance. Although the cis configuration was initially identified as the only active one, trans-platinum complexes have shown significant antitumour activity in preclinical models. In addition to mononuclear platinum compounds, multinuclear platinum complexes have been generated that are characterised by a different mode of interaction with DNA. Since a major limitation to the clinical efficacy of platinum compounds is drug resistance, the most important feature of nonconventional platinum drugs should be the capability of overcoming cellular resistance. However, due to the multifactorial nature of clinical resistance, which also involves pharmacological factors, the optimisation of current platinum-based therapy also includes the development of drug delivery approaches. The present review focuses on recent studies on the molecular alterations of tumour cells that are associated with resistance to platinum drugs, the development of novel platinum drugs, and approaches that may contribute to improve the efficacy of platinum-based therapy.

KW - Cisplatin

KW - Drug delivery

KW - Drug resistance

KW - Oxaliplatin

KW - Polynuclear platinum compounds

UR - http://www.scopus.com/inward/record.url?scp=70349381479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349381479&partnerID=8YFLogxK

U2 - 10.2174/092986709788682083

DO - 10.2174/092986709788682083

M3 - Article

VL - 16

SP - 2355

EP - 2365

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 19

ER -